More Dental Clinics Completes RMB 100 Million Series B Funding Round Led by Songbai Investment and Guoxin Venture Capital

VCBeat (WeChat: vcbeat) has learned that More Dental recently announced the completion of its Series B financing, amounting to hundreds of millions of yuan, with investors including Shuangbai Investment and Guoxin Venture Capital. Leveraging this capital infusion, More Dental is committed to building a benchmark brand for standardized, regulated, and modern dental care chains.

Headquartered in Shanghai, Moore Dental has over a decade of development history in China. As of December 2017, it had established more than 30 dental medical institutions across Shanghai (with over 20 branches), Guangzhou, Nanchang, Jiangyin, Suzhou, Nanjing, Changzhou, Jiaxing, and other regions, including Shanghai Moore Stomatological Hospital, Nantong Moore Stomatological Hospital, Taicang Moore Stomatological Hospital, Jiangyin Moore Stomatological Hospital, and Nanchang Moore Stomatological Hospital.

In March 2016, Moore Dental received investments from Shanghai Tongjiang Investment Holding Co., Ltd. and Xie Li Investment Management Co., Ltd.

In September 2017, Shanghai Stomatological Hospital, a flagship dental hospital heavily invested in by More Dental, officially opened. The four-story standalone building covers an area of over 3,500 square meters, marking a significant milestone in More Dental’s rapid development.

Moore Shanghai Stomatological Hospital features comprehensive clinical departments, including Orthodontics, Implantology, Pediatric Dentistry, VIP Special Care (Comfort Dentistry), Oral and Maxillofacial Surgery, Prosthodontics, Endodontics, Periodontics, and Preventive Dentistry. The hospital boasts a highly specialized medical team composed of renowned experts, professors, and overseas-returning scholars, such as Chief Physician Zhou Maodong, a distinguished implant specialist, and Professor Wu Liping, a leading orthodontic expert.

The hospital has established specialized clinical centers in accordance with international standards, including the Dental Implant Center, Orthodontic Diagnosis and Treatment Center, Aesthetic Restoration Center, and Pediatric Dentistry Center. It offers a comprehensive range of cutting-edge dental services, such as clear aligner therapy and lingual orthodontics, All-on-4 and digital implantology, immediate aesthetic restoration, periodontal surgical treatment, microscopic root canal therapy, and modern pediatric dentistry.

Oral healthcare is a relatively mature segment of the consumer medical industry. Favorable conditions—such as consumption upgrading, heightened patient awareness, and policy incentives encouraging private capital to enter the healthcare sector—have driven rapid growth in demand for high-end dental and aesthetic services, including dental implants, orthodontics, and teeth whitening. However, from the perspectives of dentist-to-population ratio, dental visitation rates, and dental implant penetration, China’s dental market lags significantly behind advanced global standards, indicating substantial room for growth and immense potential.

In recent years, funds of various sizes, private capital, and private equity crowdfunding have continuously invested in the dental industry chain, with dental clinics being a key target. According to statistics from VCBeat, there are 18,300 public general hospitals and specialized dental hospitals in China, along with 80,000 private dental hospitals and clinics, achieving a compound annual growth rate (CAGR) of 30%. However, the total number is only one-fourth that of the United States, and the market is dominated by standalone clinics. Chain operations and brand development are visible future trends.

Wang Sanmao, Chairman of More Dental, stated, “2017 was an extraordinary year. It marked the final year of More Dental’s First Five-Year Plan, a year in which we achieved our annual objectives and laid a more solid foundation for the future. Looking back on these years, More Dental has grown from a single small clinic into a chain of over 30 dental medical institutions, achieving a tens-fold expansion in service coverage. More Dental has never ceased its strides, committed to building the premier dental healthcare chain in the Greater Shanghai Metropolitan Area and becoming the most trusted private dentist for the people of Shanghai.”

Feng Dai, Partner at Shuangbai Investment, stated that Moore Dental possesses strong brand and channel advantages, robust management and execution capabilities, as well as an outstanding and dedicated talent team. “We are optimistic about the company’s significant potential as a leading provider of chained dental medical services and highly endorse its development goals and strategy. As a shareholder, Shuangbai Investment is honored to leverage our industrial resources in the dental sector to support the company’s further growth.”

Xu Cheng, General Manager of Guoxin Venture Capital, stated: “The core team of Moore Dental has extensive experience in the field of dental medical services, possesses a profound understanding of China’s dental healthcare industry, demonstrates strong strategic execution and outstanding refined management capabilities, and has achieved rapid yet stable growth. We have high expectations for the company’s performance in the rapidly expanding dental healthcare market.”

Wang Chao, Head of the Investment and Development Department at Moore Dental, stated, “We are optimistic about the professional expertise and resource integration capabilities that our investors, Songbo Investment and Guoxin Venture Capital, have accumulated in the healthcare sector over the long term. Leveraging this financing round as an opportunity, the company will adhere to its development strategy of building a leading regional dental brand. By capitalizing on first-mover advantages such as established brand strength and channel networks, we aim to strengthen our core regional markets, primarily in Shanghai and the Yangtze River Delta, thereby achieving sustainable growth.”

About Songbo Investment:Dedicated to investing in the healthcare industry, we provide portfolio companies with essential consulting services, including market research, brand positioning, product marketing, pharmacy management, government affairs, cross-border cooperation, and GMP-compliant manufacturing. Our team comprises senior executives from the healthcare sector and experienced investment professionals.